Rats are a common animal model for metabolism and toxicity studies. Previously, the enzymatic properties of rat flavin-containing monooxygenase (FMO) 1 purified from hepatic and renal microsomes and that of FMO3 purified from hepatic microsomes were characterized. This study investigated the physical, immunological, and enzymatic properties of FMO3 purified from male rat kidney microsomes and compared the results with those obtained with isolated rat liver FMO3. Renal FMO3 was purified via affinity columns based on the elution of L-methionine (Met) S-oxidase activity and reactivity of the eluted proteins with human FMO3 antibody. In general, Met S-oxidase-specific activity was increased 100-fold through the purification steps. The resulting protein had similar mobility (ϳ56 kDa) as isolated rat liver FMO3 and cDNAexpressed human FMO3 by SDS-polyacrylamide gel electrophoresis. When the isolated kidney protein band was subjected to trypsin digestion and matrix-assisted laser desorption ionization/time of flight mass spectral analysis, 34% of the sequence of rat FMO3 was detected. The apparent K m and V max values for rat kidney FMO3 were determined using the known FMO substrates Met, seleno-L-methionine, S-allyl-L-cysteine (SAC), and methimazole (N-methyl-2-mercaptoimidazole). The stereoselectivity of the reactions with Met and SAC were also examined using high-performance liquid chromatography. The obtained kinetic and stereoselectivity results were similar to those we obtained in the present study, or those previously reported, for rat liver FMO3. Taken together, the results demonstrate many similar properties between rat hepatic and renal FMO3 forms and suggest that renal FMO3 may play an important role in kidney metabolism of xenobiotics containing sulfur and selenium atoms.
Flavin-containing monooxygenases (FMOs) are microsomal enzymes that catalyze NADPH-and O 2 -dependent oxidation of compounds with a nucleophilic sulfur, nitrogen, phosphorus, or selenium atom. FMOs have a broad substrate range that includes pharmaceutical drugs, pesticides, industrial chemicals, and endogenous compounds. In general, FMO-mediated metabolites are more readily excreted and are less harmful than the parent compounds; however, with some chemicals, toxic metabolites are formed. Five expressed FMO isoforms (FMO1-FMO5) and six nonexpressed pseudogenes (FMO6P-FMO11P) have been characterized in humans Hernandez et al., 2004) . Each FMO isoform has a unique expression pattern that is age-, sex-, species-, and tissue-dependent.
Multiple tissue-specific mechanisms of FMO regulation have been recognized. For example, FMO1 is the principal isoform present in human fetal liver, and birth is necessary for FMO1 expression to drop to low levels (Koukouritaki et al., 2002) . The down-regulation of FMO1 in the human liver is species-dependent and tissue-specific; it does not occur in human kidney or in the liver or kidney of other mammalian species, including the rat, because of differences in upstream promoters (Shepard et al., 2007) . Differences in rabbit FMO2 expression, between high levels in pulmonary tissues and low levels in hepatic tissues, occur because of tissue-specific transcription factors that associate with DNase I-hypersensitive domains (ShehinJohnson et al., 1996) . Hormonal regulation occurs in mouse liver because FMO3 expression levels are lower in males than females because of testosterone repression (Falls et al., 1997) . It is interesting to note that the hepatic tissues of humans, rats, and rabbits do not exhibit sex-related differences in FMO3 expression (Ripp et al., 1999a; Krause et al., 2003) . FMO4 is expressed as a long form in rat kidneys and intestine and as a short form in the brain because of alternative splicing. The short form has a deletion that may be indicative of a tissue-specific structural or functional change that alters FMO4 activity or stability (Lattard et al., 2003) . Tissue-specific changes in FMO structure and function can also arise because of post-translational modifications. Hepatic pig FMO1 is N-glycosy-lated, which may alter protein folding, stability, and activity (Korsmeyer et al., 1998) . Enzymatic glycosylation cannot occur in expression systems such as Escherichia coli, but purification of the native protein allows for the characterization of substrate specificity. Finally, FMO expression in various tissues and species can be affected by xenobiotic exposure, diet, or disease (Katchamart et al., 2000; Rae et al., 2001; Tijet et al., 2006; Borbás et al., 2006) . Previously, this laboratory has purified and characterized FMO1 from rat liver and kidney using S-benzyl-L-cysteine (SBC) as the substrate (Sausen et al., 1993) . FMO1 was linked to S-oxidase activity with multiple cysteine S-conjugates, compounds in the glutathione conjugation and mercapturic acid formation pathway (Sausen et al., 1993; Ripp et al., 1997) . FMO3 was purified from rat liver using Met as the substrate (Krause et al., 1996) . Venkatesh et al. (1991) detected differences between purified hepatic and renal FMO1 from mouse tissues. Although there were many similar properties, the K m and V max for fenthion differed approximately 2-fold, and the K m for fonofos, nicotine, and thiobenzamide differed approximately 2-fold. There were also differences in n-octylamine activation and amino acid composition. Thus, a precedent of the same FMO isoform having distinct properties in different tissues exists and warrants investigation into possible differences between rat hepatic and renal FMO3 forms. FMO3 metabolizes many compounds of pharmacological and toxicological importance such as methimazole, SeMet, and cysteine Sconjugates, such as SBC. Renal FMO3 protein was detected by immunoblots in dog, rat, rabbit, and human kidneys but has never been fully characterized (Ripp et al., 1999b; Krause et al., 2003) . It is interesting to note that in dog kidney, FMO3 expression was not detected by mRNA analysis (Lattard et al., 2002) , but FMO3 protein was detected using Western blotting (Ripp et al., 1999b) . In addition, two FMO3 transcripts of 3 and 4.2 kB were detected in dog liver and lung (Lattard et al., 2002) . The two transcripts may be because of alternative 3Ј processing that affects transcript and protein stability and localization and may have a profound effect on the expression of an enzyme. Thus, it is important to use protein techniques, such as purification, to characterize renal FMO3.
In human kidney, FMO1 has high expression levels, and FMO3 has low levels (Yeung et al., 2000; Krause et al., 2003; Cashman and Zhang, 2006) . In rats, FMO3 expression is greater in the kidney than the liver (Burnett et al., 1994; Lattard et al., 2001) ; thus, rat renal metabolism may be different from human renal metabolism. Because of the metabolic significance of FMO3, the species-, sex-, and tissuerelated differences in FMO3 activity and expression are important determinants of xenobiotic metabolism. Because rats are a common animal model for metabolism and toxicity studies, and rat renal FMO3 has not been previously characterized, this study characterizes isolated rat renal FMO3 using gel electrophoresis and mass spectrometry and compares physical and metabolic activities of this enzyme with those of isolated rat liver FMO3.
Materials and Methods
Materials. NADPH, Met, Met sulfoxide, SeMet, SBC, methimazole, Cibracon Blue 3GA-agarose (type 3000-CL), and 1-fluoro-2,4-dinitrobenzene were obtained from Sigma-Aldrich (St. Louis, MO). 2,5Ј-ADP-Sepharose was obtained from GE Healthcare (Chalfont St. Giles, UK). Trypsin was sequence grade from Promega (Madison, WI). SAC was a gift from Wakunaga Pharmaceuticals of America (Mission Viejo, CA). Emulgen 911 was a gift from the Kao Atlas Corporation (Tokyo, Japan). FMO3 polyclonal rabbit anti-human antibody and cDNA-expressed human FMO3 were from BD Gentest (Woburn, MA). Met selenoxide and SAC sulfoxide were synthesized as described previously (Ripp et al., 1997; Krause et al., 2006) . Preparation of Microsomes. Kidneys and livers from male SpragueDawley rats (7-8 weeks) were received frozen on dry ice via overnight shipping (Pel-Freez Biologicals, Rogers, AR). The organs were thawed in cold buffer A (10 mM KH 2 PO 4 , 1 mM EDTA, pH 7.6) and made into "washed" microsomes by the method described previously (Sausen and Elfarra, 1990) . Microsomes were stored in 20% glycerol in FMO buffer (0.1 M KH 2 PO 4 , 0.1 M KCl, 5 mM EDTA, pH 7.4) at Ϫ80°C. Protein concentrations were determined using the bicinchoninic acid assay (Thermo Fisher Scientific, Waltham, MA) on a VERSAmax Tunable Microplate Reader (Molecular Devices, Sunnyvale, CA) using bovine serum albumin as the standard.
Purification of FMO3. Purification of FMO3 from the rat kidney and liver was carried out with slight modifications of that previously described for the hepatic FMO3 purification (Krause et al., 1996) . Kidney microsomes were thawed at 37°C and subjected to dialysis three times for 15 min each against 1 liter of buffer A at 4°C to the remove glycerol and KCl from the storage buffer. After dialysis, the microsomes were solubilized with 0.5% Emulgen 911 and centrifuged at 105,000g for 45 min at 4°C as described previously (Ripp et al., 1997) . The supernatant was filtered through glass wool and applied to a Cibacron Blue column (8 ϫ 1.5 cm) that was equilibrated with buffer B (10 mM KH 2 PO 4 , 1 mM EDTA, 0.05% Emulgen 911, pH 7.6). The column was washed with 75 ml of buffer B followed by elution with a KCl gradient from 0 to 1.25 M KCl in buffer B (35 ml each), and 1.5-ml fractions were collected. Every other fraction was assayed with 10 mM Met and 6 mM SBC for S-oxidase activity. SBC S-oxidase activity was used to determine the location of FMO1. Fractions that exhibited high Met S-oxidase activity with stereoselectivity for the formation of the D-isomer and reacted with anti-human FMO3 antibody were combined (Blue Pool I). Blue Pool I was dialyzed four times against 1 liter of buffer A for 20 min. Blue Pool I was applied to a smaller (7 ϫ 1 cm) Cibacron Blue column and washed with 30 ml of buffer B. The protein was eluted with a gradient of 0.05 to 1.25 M KCl in buffer B (20 ml each) and collected in 1-ml fractions. The fractions from the second Cibacron Blue column were assayed with 10 mM Met for S-oxidase activity. Fractions were pooled and dialyzed as described above (Blue Pool II). Blue Pool II was applied to a 2Ј,5Ј-ADP-Sepharose column (3 ϫ 0.5 cm) and washed with 10 ml of buffer B. The fractions were eluted by 0.4 mM NADPH in buffer B and collected in 1-ml fractions. Fractions were combined and dialyzed as described above (ADP Pool).
Enzymatic Assays. Enzymatic assays were performed in a similar manner to Ripp et al. (1997) and Krause et al. (2006) . Assays were performed in a Dubnoff metabolic incubator at 37°C with constant shaking in glass tubes. The protein, 2 mM NADPH, and buffer A were preincubated for 5 min. Control incubations were run without NADPH. The reaction was started with the addition of substrate. The final reaction volume (0.25 ml) was incubated for 20 min at 37°C. The enzymatic reaction was stopped with the addition of cold ethanol (0.25 ml). Met and SAC reaction aliquots (350 l) were derivatized by the addition of 9 l of 1-fluoro-2,4-dinitrobenzene [10% (v/v) in ethanol] and 6 l of 1 M NaHCO 3 . SeMet reaction aliquots (350 l) were derivatized by the addition of 9 l of 1-fluoro-2,4-dinitrobenzene [10% (v/v) in ethanol] and 30 l of KOH/KHCO 3 . After derivatization, the Met samples were incubated for 30 min at 37°C and then in the dark at room temperature for 6 h or overnight, and the SAC samples were incubated at 60°C for 1 h, and the SeMet samples were incubated in the dark at room temperature overnight. The methimazole assay was performed as described previously (Dixit and Roche, 1984) , based upon the reaction of the oxidized product with nitro-5-thiobenzoate to yield 5,5Ј-dithiobis(2-nitrobenzoate) and the change in absorbance at 412 nm from 0 to 3 min. Kinetics of purified rat renal FMO3 were determined with Met, SAC, SeMet, and methimazole concentration ranging from 0.5 to 10, 1 to 16, 0.05 to 5, and 0.005 to 1.0 mM, respectively. Apparent kinetic constants (K m and V max ) were determined using nonlinear regression in SigmaPlot software (Systat Software, Inc., San Jose, CA).
HPLC Analysis. HPLC analysis of the oxidation reactions was carried out using a Beckman System Gold 125 Solvent Module equipped with a Beckman Ultrasphere column (4.6 mm ϫ 25 cm) and a Beckman System Gold Detector 166 or Diode Array Detector 168 (Beckman Coulter, Fullerton, CA). The system was run at 1 ml/min, with the detector set at 360 nm for the derivatized oxidation products of Met, SAC, and SeMet and 220 nm for direct measurement of SBC sulfoxide. Injections of 20 l were made with a Gilson 234 Autoinjector (Gilson, Villier Le Bel, France), and Beckman System Gold software was used for HPLC control and data analyses. The HPLC methods were carried out with slight modifications to the procedures outlined previ-ously for the analysis of the oxidation products of Met (Ripp et al., 1999a) , SAC (Ripp et al., 1997) , and SeMet (Krause et al., 2006) . The mobile phase used for the detection of Met, SAC, and SeMet oxidation products was 1% acetonitrile (ACN) and 0.1% triflouroacetic acid (TFA), pH 4.5, for pump A and 75% ACN and 0.1% TFA, pH 4.5, for pump B. The mobile phase for detection of the SBC sulfoxide was 1% ACN, pH 2.5, for pump A and 50% ACN, pH 2.5, for pump B. The gradients were as follows: for SAC, initial 15% B at 6 min increased to 60% B over 5 min and at 14 min returned to 15% B; for Met, initial 30% B, at 5 min increased to 60% B over 5 min, at 12 min increased to 80% B over 2 min, and at 18 min returned to 30% B; for SeMet, initial 5% B, at 0.1 min increased to 10% B over 2.9 min, at 3 min increased to 50% B over 3 min, at 8 min increased to 70% B over 2 min, and at 13.5 min returned to 5% B; for SBC, initial 7% B, at 3 min increased to 35% B over 4 min, and at 13 min returned to 7% over 3 min. Quantitation of the Met, SAC, and SeMet oxidation products was carried out by comparing peak areas, corrected for the nonenzymatic activity, to standard curves with excellent correlation coefficients (r Ͼ 0.99) of chemically synthesized standards.
Electrophoresis. The purified protein was analyzed by SDS-polyacrylamide gel electrophoresis (12.5% Tris Criterion precast gel; Bio-Rad, Hercules, CA) that were run for 80 min with 200 V. Coomassie Blue staining was carried out by washing the gels in H 2 O, incubating in Imperial Stain (Thermo Fisher Scientific) for 2 h or overnight and washing in H 2 O until the bands became visible. Silver staining was carried out by the procedure in the SilverSNAP Stain kit II (Thermo Fisher Scientific). Western blotting was carried out by a semidry transfer of proteins from the gel to a Hybond-ECL nitrocellulose membrane (GE Healthcare) in transfer buffer (0.02 M Tris, 0.001 M SDS, 0.2 M glycine, 10% methanol) at 70 mA for 70 min. The nitrocellulose was incubated in blotting reagent (5% powdered milk, 0.06 M NaCl in 25 mM Tris, pH 7.5) for 1 h and washed in Tris-buffered saline with 0.1% Tween 20 multiple times. The nitrocellulose was exposed to anti-human FMO3 antibody overnight and washed and incubated in secondary goat antirabbit antibody conjugated to horseradish peroxidase (Jackson ImmunoResearch Laboratories Inc., West Grove, PA). West Pico SuperSignal (Thermo Fisher Scientific) was used for detection. Film (CL-X Posure Film; Thermo Fisher Scientific) was exposed to the nitrocellulose in a dark room for 1 to 2 min and developed.
Trypsin Digestion. The purified kidney protein band with the same mobility as cDNA-expressed human FMO3 standard was excised from the Coomassie Blue-stained gel. The excised piece was cut into small (Ͻ1 mm) pieces, washed in H 2 O, and destained in 200 l of 100 mM (NH 4 )HCO 3 /50% methanol. The gel pieces were dehydrated by exposure to 200 l of 25 mM (NH 4 )HCO 3 /50% ACN, 200 l of 100% ACN, and vacuum centrifugation. The gel pieces were rehydrated in 25 mM dithiothreitol in 25 mM (NH 4 )HCO 3 for 20 min at 56°C to reduce the disulfide bonds and 55 mM iodoacetamide in 25 mM (NH 4 )HCO 3 for 20 min in the dark to alkylate the cysteine residues. The gel pieces were washed in H 2 O, dehydrated again, and rehydrated with 30 l of 20 ng/l trypsin in 25 mM (NH 4 )HCO 3 at room temperature for 5 min and at 37°C overnight. Digested peptides were extracted from the gel pieces by exposure to 0.1% TFA and 70% ACN/25% H 2 O/5% TFA. Extracted peptides were pooled and dried down in a vacuum centrifuge. The peptides were reconstituted in 30 l of 0.1% TFA and run through a ZipTip C 18 column (Millipore Corporation, Billerica, MA) before MALDI-TOF analysis.
MALDI-TOF MS Analysis. Samples were spotted on plates using ␣-cyano-4-hydroxycinnamic acid as the matrix and were run on MALDI-TOF TOF MS (4800 MALDI TOF/TOF; Applied Biosystems/MDS Sciex, Foster City, CA) in positive mode (MALDI source with OptiBeam on-axis laser). The trypsin autolysis products (842.5094 and 2211.1046 m/z) were used for internal calibration of the spectra. The database search parameters allowed for oxidation of Met, one missed cleavage of trypsin, and up to 20 ppm mass error. The data were analyzed by Protein Prospector MS-Fit (http://prospector.ucsf.edu/).
Results
A protein with high Met S-oxidase activity and reactivity with anti-human FMO3 antibody was purified from male rat kidney microsomes. Chromatography from the first Cibacron Blue column showed that FMO3 activity elutes at approximately 0.25 M KCl, before the elution of the SBC S-oxidase, which was previously characterized as FMO1. Further purification of kidney FMO3 activity through a second Cibacron Blue column followed by a 2Ј,5Ј-ADPSepharose column typically resulted in a 100-fold increase of Met S-oxidase-specific activity (Table 1) . When the purified protein was run by SDS-PAGE and was visualized by silver staining, a strong band (Fig. 1, lane F) with the same mobility as cDNA-expressed human FMO3 (Fig. 1, lane A) was observed. Although there were a few extraneous bands of protein, the increase in purity between chromatographic steps is considerable (Fig. 1) . The purified protein in the final pool had similar mobility (ϳ56 kDa) as isolated rat liver FMO3 and cross-reacted with anti-human FMO3 antibody (Fig. 2) . The kidney protein band was excised from the Coomassie Bluestained gel, trypsin digested, and analyzed by MALDI-TOF MS. Fourteen peptides that matched to the theoretical masses of trypsin digested rat FMO3 were detected using a mass error tolerance of m/z Ϯ 20 ppm (Table 2 ). This represented 34.7% of the sequence of rat FMO3. Rat FMO3 was the most probable rat protein reported using the Protein Prospector MS-Fit software. The Gly-Xxx-Gly-XxxXxx-Gly consensus sequence for the FAD binding site at amino acid residues 9 to 14 was detected at 1353.8232 m/z as part of a longer peptide. The Gly-Leu-Gly-Asn-Ser-Gly consensus sequence for NADPH binding at residues 191 to 196 was detected at 3006.6041 m/z as part of a longer peptide. In addition, a pentapeptide from residues 24 to 28, which is a highly conserved region of FMOs, was detected as part of a longer peptide at 1726.7610 m/z. It is interesting to note that there were only two peptide matches to rat FMO1, with 3.8% coverage of the protein and eight peptide matches to rat FMO4 (one peptide also matched FMO3) with 15% coverage of the protein. The Mowse scores, which are determined using an algorithm where each peptide matched is given a statistical weight, for FMO1 and FMO4 are 4.3 and 387, respectively, which are much lower than the Mowse score for FMO3 (1.06 ϫ 10 9 ) (Protein Prospector MS-Fit). Incubation of purified rat renal FMO3 with 10 mM Met and 2 mM NADPH led to detection of Met sulfoxide that was typically 80% in the D-isomer form, with a specific activity of approximately 150 nmol/mg protein/min. Purified renal FMO3 with 15 mM SAC typically resulted in sulfoxide formation that was 60% of the latter, eluting diastereomer with a specific activity of approximately 200 nmol/mg protein/min. The activities and stereoselectivities were corrected by subtraction of nonenzymatic activity detected in samples without NADPH, which had little sulfoxide formation that was 55% of the Met sulfoxide D-isomer and 45% of the SAC sulfoxide later eluting isomer. The kinetic parameters for known FMO3 substrates determined with rat renal FMO3 are summarized in Table 3 , and corresponding parameters for the purified hepatic FMO3 are included for comparison. Nonlinear regression of the kinetic data is shown in Fig. 3 . K m values determined with purified rat renal FMO3 with methimazole, SeMet, Met, and SAC were 0.04, 0.35, 2.8, and 4.3 mM, respectively. V max values determined with purified rat renal FMO3 for methimazole, SeMet, Met, and SAC were 101, 1148, 253, and 219 nmol/mg protein/min, respectively. The kinetic values obtained may be slightly affected by the extraneous proteins visible by SDS-PAGE and silver staining in the purified renal FMO3 pool. The rat kidney FMO3 kinetic parameters for SeMet and SAC were similar to the corresponding values obtained with the isolated rat liver FMO3.
Discussion
This study investigated the physical and immunological properties of rat renal FMO3 and characterized the kinetics with Met, SAC, SeMet, and methimazole. The KCl concentration that eluted FMO3 from the Cibacron Blue column was similar to the KCl concentration used to elute rat liver FMO3. The purification included two Cibacron Blue columns with different KCl gradients to ensure separation of FMO3 from FMO1. Using our purification scheme, the kidney protein was purified approximately 100-fold as indicated by Met S-oxidasespecific activity. This is similar to the results we obtained with the rat liver, where FMO3 was purified 109-fold using similar methods (data not shown). Krause et al. (1996) previously reported a 72-fold enrichment of rat liver FMO3 using similar columns and Met as the substrate, whereas Sadeque et al. (1993) reported a 77-fold enrichment of macaque liver FMO3 using two ion exchange columns and a 2Ј,5Ј-ADP Sepharose column and methyl p-tolyl sulfide as the substrate.
The purified protein was run by SDS-PAGE to determine its approximate molecular mass and assess purity (Fig. 1) . The number of bands in the final pool is drastically reduced, although there are still a few extraneous proteins, between 31 and 45 kDa. The major band exhibited a molecular mass (ϳ56 kDa) similar to the molecular mass obtained in the present study for hepatic FMO3 (Fig. 2) and the molecular mass previously reported for rat liver FMO3 (Krause et al., 1996) .
The purified kidney protein exhibited a band with the same mobility as cDNA-expressed human FMO3 by SDS-PAGE that also reacted with anti-human FMO3 antibody. The antibody used is intended for a human FMO3, which has 81% similar sequence identity to rat FMO3 (Lattard et al., 2001) ; thus, it is not surprising that rat FMO3 reacts with the anti-human antibody. This band was stained with Coomassie Blue and was subjected to in-gel trypsin digestion and MALDI-TOF MS analysis. Trypsin cleaves peptides at the carboxyl side of the amino acids lysine and arginine, except when either is followed by a proline, allowing a search for peptides of known mass. We selected search parameters that allowed for one missed cleavage by trypsin, Ϯ20 ppm mass error, and the variable oxidation of Met. The peptides detected covered 34.7% of the rat FMO3 sequence. The coverage included the FAD (amino acids 9 -14) and NADPH (amino acids 191-196) binding regions. It also included a highly conserved pentapeptide that is present in rabbit, human, and mouse FMO3 and rat FMO1 (Lattard et al., 2001) . FMO3 was the highest scored rat protein (Protein Prospector MS-Fit). To our knowledge, this is the first confirmation of the rat FMO3 amino acid sequence from native protein. Notably, it is difficult to identify membrane proteins via MALDI-TOF analysis because of the low abundance, the low solubility that necessitates detergents, and the tendency for the proteins to aggregate. The method described above, which combines enrichment before electrophoresis and in-gel digestion, may be a useful way to obtain a peptide mass fingerprint of membrane-associated proteins.
There are three predicted putative consensus sequences (Asn-XxxSer/Thr, Xxx Pro) for N-glycosylation in rat FMO3 (Asn61, 275, and 422). Two of these sequences (Asn61 and 275) were detected as unmodified peptides by MALDI-TOF (Table 2) , suggesting N-glycosylation in the native protein at these sites is incomplete or does not occur. However, it should be noted that identification of glycosylated 
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at ASPET Journals on June 16, 2017 dmd.aspetjournals.org peptides solely by MALDI-TOF MS is not certain because of the variety of glycans that could be linked to the peptides. Hepatic pig FMO1 was previously shown to be N-glycosylated at Asn120 using endoglycosidase-H digestion, plant lectin binding studies, and highperformance liquid chromatography/electrospray ionization/mass spectrometry in conjunction with computer algorithms to search for multiple hypothetical high-mannose glycopeptides (Korsmeyer et al., 1998) . Despite being N-glycosylated, Asn120 was also detected as an unmodified peptide, suggesting that N-glycosylation of Asn120 in hepatic pig FMO1 was incomplete.
The kinetic parameters for rat renal FMO3 are similar to the hepatic form. Methimazole is the highest affinity substrate tested, followed by SeMet, Met, and SAC. This is the same substrate affinity order as hepatic FMO3 (Table 3 ). The small differences in kinetic values are within the normal range of variability in kinetic assays on purified proteins and provide evidence that the enzymes have the same catalytic properties.
Met, an essential amino acid that is toxic in high doses, is metabolized by rat renal FMO3 to Met sulfoxide, with a K m value of 2.8 mM and a V max value of 253 nmol/mg protein/min. This is similar to what was observed with purified rat liver FMO3 (K m ϭ 3.4 mM and V max ϭ 261 nmol/mg protein/min) (Krause et al., 1996) . Normal plasma Met concentrations (40 -60 M) are too low for FMO3 to significantly contribute to Met metabolism, but higher plasma Met levels (0.05-1.9 mM), near the K m of FMO3, were observed in patients with homocystinuria, methionine adenosyltransferase deficiency, and impaired chronic liver disease (Gahl et al., 1988; Tangerman et al., 2000; Bosy-Westphal et al., 2003) .
Rat renal FMO3 metabolized SeMet to methionine selenoxide with a K m value of 0.35 mM and V max value of 1148 nmol/mg protein/min.
The kinetic values correspond closely with purified rat liver FMO3 (K m ϭ 0.31 mM and V max ϭ 1347 nmol/mg protein/ min). Krause et al. (2006) previously reported values (K m ϭ 0.11 mM and V max ϭ 280 nmol/mg protein/min) for SeMet metabolism by isolated rat liver FMO3 that differ from the values obtained in the present study. The difference in V max values among the studies may be because of experimental errors in quantifying low protein levels or differences in the duration of storage of the purified proteins. The low K m and high V max values obtained in the present study for both hepatic and renal FMO3 indicate that renal FMO3 may have a role in the metabolism of SeMet in vivo. SeMet is a common dietary source of selenium, an essential micronutrient that is acutely and chronically toxic when given at high levels. Tissue selenium levels have also been related to a reduced incidence of certain cancer; thus, SeMet is taken as a nutritional supplement. It is noteworthy that SeMet has been shown to bioaccumulate in the kidney and liver in a dose-dependent manner (Tashjian et al., 2006) . Taken together, this indicates SeMet levels in the kidney could be affected by FMO3 metabolism.
Methimazole is a prescribed treatment for hyperthyroidism and an antioxidant that protected the rat kidney against the nephrotoxicity of S-(1,2-dichlorovinyl)-L-cysteine, 2-bromohydroquinone, cephaloridine, cis-diamminedichloroplatinum, and gentamicin (Sausen et al., 1991; Elfarra et al., 1994) . Renal FMO3 metabolizes methimazole with a K m value of 0.04 mM and a V max value of 101 nmol/mg protein/min. The K m values are similar to the kinetics obtained with heterologously expressed rat FMO3 (K m ϭ 0.04 mM and V max ϭ 200 nmol/mg protein/min) and purified rat liver FMO3 (K m ϭ 0.01 mM and V max ϭ 168 nmol/mg protein/min) (Krause et al., 1996; Lattard et al., 2001) .
SAC, a component of garlic and model cysteine S-conjugate, has antioxidant activities that protects against aging, cancer, and reactive oxygen species damage by CCl 4 (Kodai et al., 2007) , acetaminophen (Hsu et al., 2006) , and alcohol in the liver (Yan and Yin, 2007) . SAC sulfoxide can also act as an antioxidant to prevent damage in nicotinetreated rats (Helen et al., 2003) and in isoproterenol-induced myocardial ischemia (Sangeetha and Quine, 2006) . Rat renal FMO3 had a K m value of 4.3 mM and a V max value of 219 nmol/mg protein/min. The K m value is similar to the value we obtained with purified hepatic rat FMO3 (K m ϭ 5.9 mM and V max ϭ 130 nmol/mg/min) and cDNAexpressed rabbit FMO3 (K m ϭ 5.5 mM and V max ϭ 18.2 nmol/nmol flavin/min) (Ripp et al., 1997) . To our knowledge, no kinetic determination with SAC has been performed on purified rat FMO3 previously. The detection of the sulfoxide in rat urine after dosing with SAC provides evidence that this reaction takes place in vivo (Krause et al., 2002) , although the high K m of FMO3 suggests that other FMO isoforms or enzymes may also be involved. Taken together, the results presented in this manuscript demonstrate many similar properties between rat hepatic and renal FMO3 forms. Furthermore, the results suggest renal FMO3 may play a role in xenobiotic biotransformation in the kidney and may aid in future metabolism studies. 
